Aromatase Inhibitor-Associated Bone Loss in Breast Cancer
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1.Patients who receive breast cancer treatment with aromatase inhibitor at our hospital 2.Treatment of osteoporosis in "Women's HealthCare Outpatient clinic for Breast Cancer Patients" 3.Using Bisphosphonate or denosumab for osteoporosis 4.Osteoporosis treatment has been started and continued with the same drug for more than 2 year
Exclusion criteria
Exclusion criteria: 1.Patients who received continuous administration of osteoporosis before visit "Women's HealthCare Outpatient clinic for Breast Cancer Patients" 2.Has bone metastases 3.changed drug on the way
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| TBS(Trabecular Bone Score) and rate of change before, 6,12,18 and 24 months after the start of osteoporosis treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Bone density and bone metabolism markers and rate of change before, 6,12,18 and 24 months after the start of osteoporosis treatment | — |
Countries
Japan
Contacts
Yokohama City University Medical Center Department of Gynecology